The emergence of AI and biosensors offers a chance to address inefficiencies in drug development.

In today’s ACT Brief, we cover how AI is being deployed to optimize global trial design, why ESG performance is emerging as a ...

Raja Shankar, VP of machine learning at IQVIA, discusses which AI capabilities sponsors are most likely to adopt first to ...

TORONTO, April 3, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming ...

Community collaboration is just as essential as a tailored clinical trial design to best investigate the effects of a disease on a specific patient population, Amir Fathi, MD, director of the leukemia ...

Note: This is the third article of a three-part series. Real-world evidence (RWE) plays a crucial role in supporting the benefits of one drug over another in debates that play out on the boards and ...

Speakers at the 2024 World Conference on Lung Cancer discussed the considerations that must go into designing and performing clinical trials in the early-stage lung cancer space, ranging from ...

GSK and Genomics plc will collaborate on a new precision medicine initiative that assesses how genetic data can be used in clinical trial design, Genomics announced April 30. The project will look at ...

Clinical trials often suffer from a lack of participant diversity, resulting in findings that may not fully represent the eventual treated patient population. This issue has improved only modestly in ...

Eli Lilly believes community-based clinical trials are the wave of the future and is pushing sponsors to embrace the paradigm as a way to boost enrollment and diversity. “In the future, I think we’ll ...